Recent Updates — GDTC
The Nasdaq Stock Market notified CytoMed Therapeutics that its ordinary shares failed to maintain the required minimum bid price of $1.00 for 30 consecutive business days ending October 5, 2026. The company has a compliance period until April 5, 2027, to restore the share price to at least $1.00 for ten consecutive trading days. Failure to regain compliance may result in delisting proceedings or require a reverse stock split to meet listing standards. CytoMed Therapeutics is a clinical-stage biopharmaceutical company developing cell-based immunotherapies.
CytoMed Therapeutics Limited filed its Unaudited Interim Condensed Consolidated Financial Statements for the six months ended June 30, 2026. The company reported a net loss of S$1.79 million (US$1.39 million), a 20.1% decrease from the S$2.25 million loss in the same period last year. Revenue from private blood banking services increased marginally to S$157,289, while other operating income declined to S$254,719 due to lower interest and research income. Cash balances decreased to S$1.46 million as net cash used in operations totaled S$1.65 million. Financing activities generated S$963,664, primarily from a S$699,600 loan from a director and S$300,000 from non-controlling interest share issuance. The company also disclosed an ATM sales agreement allowing up to US$4.30 million in equity sales, with US$237,550 raised to date. CytoMed Therapeutics Limited operates as a clinical-stage biopharmaceutical company developing allogeneic cell-based immunotherapies for cancers and degenerative diseases.
On June 22, 2026, Chairman and Director Mr. Choo Chee Kong offered to acquire between 100,000 and 200,000 company shares from independent shareholders via private purchase agreements. Additionally, Mr. Choo, through EP Capital Inc., invested S$300,000 (approximately US$250,000) into LongevityBank Pte Ltd, a company subsidiary. This investment increased EP Capital Inc.'s stake in LongevityBank from 6.4% to 12.0% based on a S$5 million post-money valuation. Funds will be used to establish an R&D laboratory for product innovation and process improvement. CytoMed Therapeutics operates in the biotechnology industry, focusing on cord blood banking and the development of cord blood-derived therapeutics.